Navigation Links
Regeneron Announces February 2012 Investor Conference Presentations
Date:2/21/2012

TARRYTOWN, N.Y., Feb. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:

  • Citi 2012 Global Healthcare Conference at 3:00 p.m. Eastern Time on Tuesday, February 28, 2012
  • RBC Capital Markets' Healthcare Conference at 9:00 a.m. Eastern Time on Wednesday, February 29, 2012
  • The sessions may be accessed through the Company's web site, www.regeneron.com, on the Events and Presentations page.  Archived versions of the presentations will be available for thirty days after the live webcasts. 

    Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA® (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:  

     Manisha Narasimhan, Ph.D.

    Peter DworkinInvestor Relations

    Corporate Communications914-847-5126

    914.847.764manisha.narasimhan@regeneron.com

    peter.dworkin@regeneron.com


    '/>"/>
    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
    2. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
    3. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
    4. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
    5. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
    6. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
    7. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
    8. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
    9. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
    10. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
    11. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2017)... Jan 23, 2017 Research and Markets has announced ... Trends - Product - Forecast to 2025" report to their offering. ... Report Highlights: ... market trends to identify the investment opportunities Market forecasts ... Key market trends across the business segments, Regions and Countries ...
    (Date:1/23/2017)... Jan. 23, 2017  Using Astute Medical,s ... risk for acute kidney injury (AKI) after open-heart ... care guidelines significantly improved outcomes by ... more than 33 percent, according to a ... Intensive Care Medicine. Experience ...
    (Date:1/23/2017)... January 23, 2017 Ahead of today,s trading ... how they have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... were relative laggards on Friday, January 20 th , 2017, down ... research reports on these stocks now at: ...
    Breaking Medicine Technology:
    (Date:1/23/2017)... ... January 23, 2017 , ... The Masters of Science ... evaluation leaders with decades of experience who remain current practitioners in the field. ... system, there is a renewed demand for versatile, data-driven leadership.The American University’s MS ...
    (Date:1/23/2017)... ... January 23, 2017 , ... Moisture measurement is a ... method is paramount to success. Selecting an inappropriate measurement method can cause costly ... use the same equipment. Rare or expensive substances are wasted and production may ...
    (Date:1/23/2017)... ... January 23, 2017 , ... Gynecology Associates of ... gynecological services for women of all ages. The staff of Gynecology ... of reproductive services from routine health screenings to diagnosing and treating female concerns ...
    (Date:1/23/2017)... ... ... “Some Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the ... of published author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He ... nineteen, a pastor for over fifteen years. He is a graduate of N.C. College ...
    (Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals and ... a simple test will take days to arrive to the end customer, having to ... access to their lab tests, bypassing the cost and delay of traditional means. Now ...
    Breaking Medicine News(10 mins):